DRKS00028305招募中不适用
Prospective, descriptive, non-interventional, German multicenter study to evaluate the quality of life of Wilson disease patients after switching from D-penicillamine to trientine tetrahydrochloride and to assess clinical and patient reported outcomes - PACUS
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •Patients with provided written informed consent form (ICF) and a data protection consent.
- •Adult patients (= 18 years) of any gender diagnosed with Wilson disease (ICD-10 E83.0).
- •Patients previously treated with DPA with intolerance of the medication, which leads to a medication switch to Cuprior®. Patients should require a therapy switch from current DPA to Cuprior® treatment based on physician assessment and approval and before enrollment in the study.
排除标准
- •Patients without filed prescription of Cuprior® or existing evidence of decision to switch.
- •Patient without recorded manifestation of DPA intolerance.
- •Patients with anticipated impossibility to be followed up for any reasons.
- •Patients switched to other Wilson disease therapies (trientine dihydrochloride, zinc salts).
研究者
相似试验
进行中（未招募）
Unknown
Observational study of a motion capture device (AKIRA) in patients with ALSJPRN-jRCT1030230648Hirai Manabu35
招募中
不适用
Impact of mental health and stress on Physical Recovery of Patients after Total Joint ReplacementCTRI/2022/03/041238Self funded Mrs Shilpi Singh
已完成
Unknown
A study to evaluate the performance of software ‘AITRICS-VC’ for predicting sepsis, and major adverse events in a general ward inpatient using EMR dataCertain infectious and parasitic diseasesKCT0008466Aitrics10,500
尚未招募
4 期
A post marketing surveillance study of Moxifloxacin Hydrochloride solution to check its ability to prevent the growth or spread of bacteria & its safety in patient undergoing ophthalmic surgery.CTRI/2023/12/060575ovartis Healthcare Private Limited
尚未招募
不适用
A prospective, open-label, non-interventional phase IV study to investigate the COgnitive status, MOod, fatigue and quality of life in relapsing remitting multiple sclerosis patients treated with teriflunomide (Aubagio®) in Daily routine Observational Setting.NL-OMON25460120